Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
|Metastatic Pancreatic Adenocarcinoma Metastatic Pancreatic Cancer||Drug: Nab-Paclitaxel Drug: Gemcitabine Drug: Indoximod||Phase 1 Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas|
- Phase 2 Dosing [ Time Frame: 10 months ]
Phase 1 component:
To determine recommended phase 2 dose of indoximod when administered with a standard of care chemotherapy backbone consisting of gemcitabine plus nab-paclitaxel.
- Regimen Limiting Toxicity [ Time Frame: 10 months ]
Phase 1 component:
To identify the regimen limiting toxicity (RLT) for the combination of the immunotherapeutic agent indoximod when administered in combination with standard of care chemotherapy gemcitabine plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas.
RLT will be considered as only grade 3 and 4 toxicities that are attributable to the test agent and result in the delay of the administration of the backbone chemotherapy, gemcitabine plus nab-paclitaxel.
- Overall Survival [ Time Frame: 22 months ]
Phase 2 component:
To evaluate efficacy as determined by overall survival (OS) in patients with metastatic adenocarcinoma of the pancreas.
- Biomarker Response [ Time Frame: 22 months ]A secondary objective is to examine biomarker responses of gemcitabine and nab-paclitaxel with indoximod through the evaluation of serum for biomarkers of IDO activity (kynurenine and tryptophan), before and after initiation of therapy through specimen collection at protocol specified timepoints.
- Response Rate [ Time Frame: 22 months ]To determine the response rate of the combination indoximod with gemcitabine plus nab-paclitaxel. Imaging assessments to be performed at protocol-specified time points and evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).
- Time to Progression of Disease [ Time Frame: 22 months ]To determine the time to progression with the combination indoximod with gemcitabine plus nab-paclitaxel. Progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).
|Study Start Date:||August 2014|
|Estimated Study Completion Date:||July 2018|
|Estimated Primary Completion Date:||July 2017 (Final data collection date for primary outcome measure)|
Experimental: Indoximod and Gemcitabine + Nab-paclitaxel
Phase 1 portion:
Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.
Phase 2 portion:
Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout.
Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Other Names:Drug: Gemcitabine
Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Other Name: GemzarDrug: Indoximod
Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth
Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity.
This is a Phase I/II trial designed to evaluate the combination of the immunotherapeutic agent indoximod and the standard of care chemotherapy gemcitabine plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas. The phase 1 portion is designed to identify the regimen-limiting toxicity (RLT) and recommended phase 2 dose (RP2D) for the combination. The phase 2 portion of the study will evaluate the potential efficacy of this combination. All subjects will receive the standard 28-day gemcitabine plus nab-paclitaxel regimen. Twice daily oral indoximod will be administered concurrently in continuous 28 day cycles.
In the phase 1 portion, dose escalation of indoximod will begin at 600mg/day and potentially escalate to 1200mg/day. There will be no intra-subject dose escalation. Regimen-limiting toxicity will be considered as those toxicities related to indoximod that significantly limit the administration of the backbone chemotherapy gemcitabine plus nab-paclitaxel. The period for determination of dose-limiting toxicities will be the initial 28 days of treatment. The recommended phase 2 dose will include an assessment of toxicities that occur at later time points.
Once a RP2D is determined, the phase 2 portion of the study will be initiated. In both phase 1 and phase 2, every 2 cycles subjects will have repeat imaging to assess response. Corollary biomarkers will be assessed at the same interval as will PET-CT after the 1st 8 week cycle. Up to 18 patients will be enrolled in the phase 1 portion of the study and 80 patients will be enrolled in the phase 2 portion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02077881
|United States, California|
|Palo Alto, California, United States, 94304|
|Contact: Benjamin Priestley 650-723-2990|
|Principal Investigator: Sigurdis Haraldsdottir, MD, PhD|
|United States, Georgia|
|Georgia Regents University||Recruiting|
|Augusta, Georgia, United States, 30912|
|Contact: Robbin Dobbins, RN 706-721-2154 email@example.com|
|Principal Investigator: Samir Khleif, MD|
|United States, Kentucky|
|University of Kentucy||Recruiting|
|Lexington, Kentucky, United States, 40536|
|Contact: Stephanie Malicote 404-785-0232|
|Principal Investigator: Peter Hosein, MD|
|United States, Missouri|
|Washington University in St. Louis||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Kimberly Lears 314-747-8085 firstname.lastname@example.org|
|Principal Investigator: Andrea Wang-Gillam, MD|
|United States, New Jersey|
|The Vally Hospital||Recruiting|
|Paramus, New Jersey, United States, 07652|
|Contact: Stephanie Blash 201-634-5792|
|Principal Investigator: Jin Lee, MD|
|United States, Pennsylvania|
|University of Pittsburgh Medical Center||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15232|
|Contact: Natalie Streeter 412-235-1276 email@example.com|
|Principal Investigator: Nathan Bahary, MD|
|United States, South Carolina|
|Greenville Health Systems||Recruiting|
|Greenville, South Carolina, United States, 29605|
|Contact: Lisa Johnson, RN 864-455-3600|
|Contact: Jill Cantrell, RN|
|Principal Investigator: Mark O'Rourke, MD|
|Gibbs Cancer Center and Research Institute||Recruiting|
|Spartanburg, South Carolina, United States, 29303|
|Contact: Kenneth Kuenzli, RN 864-560-7579|
|Principal Investigator: Caio Rocha-Lima, MD|
|United States, Tennessee|
|The West Clinic||Recruiting|
|Memphis, Tennessee, United States, 38120|
|Contact: Cindy Inman, RN 901-683-0055 firstname.lastname@example.org|
|Principal Investigator: Bradley Somer, MD|
|United States, Utah|
|Huntsman Cancer Center||Recruiting|
|Salt Lake City, Utah, United States, 84112|
|Contact: Rachel Kingsford, MS 801-585-0115 email@example.com|
|Principal Investigator: Ignacio Garrido-Laguna, MD|
|United States, Vermont|
|University of Vermont Medical Center||Recruiting|
|Burlington, Vermont, United States, 05401|
|Contact: Debbie McAdoo 802-656-9113 firstname.lastname@example.org|
|Principal Investigator: Maura Barry, MD|
|Study Chair:||Nicholas Vahanian, MD||NewLink Genetics Corporation|